Tag Archives: difference

There Appears to Be a Huge Problem With SpaceX’s Starlink – Futurism

Posted on by

Did Elon Musk fib about the service breaking even? Balance Sheet

In a brief announcement on his social media platform last year, SpaceX CEO Elon Musk celebrated that the company's Starlink broadband service had "achieved breakeven cash flow."

"Starlink is also now a majority of all active satellites and will have launched a majority of all satellites cumulatively from Earth by next year," he said at the time.

But according to a damning new report by Bloomberg, Musk may have once again rigged the numbers in his favor by greatly underplaying the costs involved in launching the satellites, when in reality the company is losing "hundreds of dollars on each of the millions of ground terminals it ships."

According to Bloomberg's sources, SpaceX's accounting was "more of an art than a science" and the much-hyped system isn't actually profitable, despite Musk's assurances.

The company has kept its financials close to its chest, especially while fundraising. During a March press conference, SpaceX CFO Bret Johnsen appeared cagey, telling reporters in a carefully worded comment that "I dont know that I want to quantify those numbers, but we are in positive cash flow and profitable territory for our satellite business now."

In short, is SpaceX's Starlink business cashflow positive, as Musk claims, or merely in "profitable territory"? The distinction could make all the difference for Musk's outsize plans for space colonization.

The mercurial CEO has long argued that the internet satellite broadband arm of his space company will provide the funding necessary to get humans to Mars. According to Bloomberg, Starlink represents more than half of SpaceX's revenue this year.

As of now, SpaceX has launched 5,600 satellites into low-Earth orbit and is planning to launch tens of thousands more.

Despite eclipsing the total number of all operating satellites in Earth's orbit, Starlink isn't just struggling to cut even. Experts are concerned that trying to provide the entire globe with internet via satellites instead of expanding coverage with cell towers where needed could prove difficult, with speeds already beginning to decrease in 2022.

In other words, SpaceX will have to pump out untold numbers of satellites to keep up with quickly growing bandwidth demands.

That's not all the bad news. According to Bloomberg, all major US airlines have rejected SpaceX's Starlink to provide internet service on flights, though an exact reason as to why remains unclear.

Nonetheless, SpaceX has exceeded expectations when it comes to generating revenue over the years. Sales could grow from $4.7 billion a year ago to $15 billion this year, per Bloomberg's sources.

SpaceX may end up spinning off its internet service with a potential IPO. But that's still years out, according to company officials.

More on Starlink: SpaceX Announces Plans to Set 100 Starlink Satellites on Fire

Follow this link:

There Appears to Be a Huge Problem With SpaceX's Starlink - Futurism

James Shapiro, MD: Insulin Production In T1D Patients After Stem Cell Therapy – MD Magazine

Posted on by

Recently, data from studies developing novel cell replacement therapies to address significant unmet needs in severe disease, including type 1 diabetes (T1D).

The study in question is an ongoing, first-in-human Phase study that reported that its stem-cell therapy produced insulin in people with severe T1D. A total of 17 patients were implanted with the ViaCyte PEC-Direct device at 6 different centers, with the device comprising pancreatic cells (PEC-01) contained within pouches for subcutaneous placement.

In an interview with HCPLive, James Shapiro MD PhD, Canada Research Chair and Director of the Islet Transplant Program at the University of Alberta and lead author of the Cell Reports Medicine report, discussed the findings of the study and what they ultimately represent.

It was a very successful trial in terms of demonstrating the safety, it was absolutely safe for patients, while they were, you know, many different potential side effects on the anti rejection drugs and the minor surgeries that the patients went through, they tolerated the placement and the removal of the devices exceedingly well, Shapiro said.

The trial results indicated 34% of patients had evidence of C-peptide production, while 63% of patients had evidence of surviving insulin producing cells at different time points when the devices were taken out and examined under a microscope.

Shapiro went on to describe the next wave of trials using gene-edited products that will not require anti-rejection drugs, called PEC-QT. He noted the difference between a treatment and a cure is the limitless source of cells and lack of need for rejection drugs.

I think if that happened, then we really would have a therapy that could be given to children just diagnosed with diabetes, they could be given to patients with all forms of diabetes, not just patients with T1D, he said. So, I think this does herald a big step forward for for stem cell based therapists in the cure potential curative treatment for all forms of diabetes.

Read more here:

James Shapiro, MD: Insulin Production In T1D Patients After Stem Cell Therapy - MD Magazine